BMC Medicine (Oct 2017)

A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria

  • Fiona Macintyre,
  • Yeka Adoke,
  • Alfred B. Tiono,
  • Tran Thanh Duong,
  • Ghyslain Mombo-Ngoma,
  • Marielle Bouyou-Akotet,
  • Halidou Tinto,
  • Quique Bassat,
  • Saadou Issifou,
  • Marc Adamy,
  • Helen Demarest,
  • Stephan Duparc,
  • Didier Leroy,
  • Bart E. Laurijssens,
  • Sophie Biguenet,
  • Afizi Kibuuka,
  • Antoinette Kitoto Tshefu,
  • Melnick Smith,
  • Chanelle Foster,
  • Illse Leipoldt,
  • Peter G. Kremsner,
  • Bui Quang Phuc,
  • Alphonse Ouedraogo,
  • Michael Ramharter,
  • on behalf of the OZ-Piperaquine Study Group

DOI
https://doi.org/10.1186/s12916-017-0940-3
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 19

Abstract

Read online

Abstract Background The clinical development of a single encounter treatment for uncomplicated malaria has the potential to significantly improve the effectiveness of antimalarials. Exploratory data suggested that the combination of artefenomel and piperaquine phosphate (PQP) has the potential to achieve satisfactory cure rates as a single dose therapy. The primary objective of the study was to determine whether a single dose of artefenomel (800 mg) plus PQP in ascending doses is an efficacious treatment for uncomplicated Plasmodium falciparum malaria in the 'target' population of children ≤ 5 years of age in Africa as well as Asian patients of all ages. Methods Patients in six African countries and in Vietnam were randomised to treatment with follow-up for 42–63 days. Efficacy, tolerability, safety and pharmacokinetics were assessed. Additional key objectives were to characterise the exposure–response relationship for polymerase chain reaction (PCR)-adjusted adequate clinical and parasitological response at day 28 post-dose (ACPR28) and to further investigate Kelch13 mutations. Patients in Africa (n = 355) and Vietnam (n = 82) were included, with 85% of the total population being children 95% PCR-adjusted ACPR at day 28. Achieving very high efficacy following single dose treatment is challenging, since > 95% of the population must have sufficient concentrations to achieve cure across a range of parasite sensitivities and baseline parasitaemia levels. While challenging, the development of tools suitable for deployment as single encounter curative treatments for adults and children in Africa and to support elimination strategies remains a key development goal. Trial registration ClinicalTrials.gov, NCT02083380 . Registered on 7 March 2014.

Keywords